Sanofi to market Pozen drugs for Gastric Ulcer in US
Sanofi and Pozen have signed an exclusive license agreement for the commercialization of Pozens' proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor and enteric-coated (EC) aspirin in a single tablet , PA8140 and PA32540. Under the terms of the agreement, Sanofi will have exclusive rights to commercialize all PA combinations that contain 325 mg or less of enteric-coated aspirin in the United States.
The NDA was submitted in March 2013 and accepted for filing in May 2013 by the FDA.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins